BioLife Solutions Inc (BLFS)vsMedline Inc. Class A Common Stock (MDLN)
BLFS
BioLife Solutions Inc
$29.15
-3.67%
HEALTHCARE · Cap: $1.36B
MDLN
Medline Inc. Class A Common Stock
$39.79
-3.21%
HEALTHCARE · Cap: $71.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 28564% more annual revenue ($29.14B vs $101.66M). MDLN leads profitability with a 3.3% profit margin vs -2.9%. MDLN earns a higher WallStSmart Score of 50/100 (D+).
BLFS
Avoid30
out of 100
Grade: F
MDLN
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-9.0%
Fair Value
$20.42
Current Price
$29.15
$8.73 premium
Intrinsic value data unavailable for MDLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.7% year-over-year
Earnings expanding 1258.0% YoY
Large-cap with strong market position
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 0.1%
Expensive relative to growth rate
ROE of -2.8% — below average capital efficiency
Premium valuation, high expectations priced in
Distress zone — elevated risk
3.3% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BLFS
The strongest argument for BLFS centers on Debt/Equity, Altman Z-Score, Revenue Growth. Revenue growth of 24.7% demonstrates continued momentum.
Bull Case : MDLN
The strongest argument for MDLN centers on EPS Growth, Market Cap, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.
Bear Case : BLFS
The primary concerns for BLFS are Market Cap, Operating Margin, PEG Ratio.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
BLFS profiles as a growth stock while MDLN is a value play — different risk/reward profiles.
BLFS is growing revenue faster at 24.7% — sustainability is the question.
MDLN generates stronger free cash flow (316M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDLN scores higher overall (50/100 vs 30/100) and 10.7% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioLife Solutions Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?